3'-Azido-3'-deoxy-5-methyl-beta-L-cytidine manufacturers
|
| | 3'-Azido-3'-deoxy-5-methyl-beta-L-cytidine Basic information |
| Product Name: | 3'-Azido-3'-deoxy-5-methyl-beta-L-cytidine | | Synonyms: | 3'-Azido-3'-deoxy-5-methyl-beta-L-cytidine;3’-Azido-3’-deoxy-5-methyl-β-L-cytidine;3'-Azido-3'-deoxy-5-methyl-b-L-cytidine;3’-Azido-3’-deoxy-5-methyl-beta-L-cytidine;1-methanesulfonyl-4-[1-(3-methyl-1H-pyrazole-5-carbonyl)pyrrolidin-3-yl]piperidine | | CAS: | 2095417-52-8 | | MF: | C10H14N6O4 | | MW: | 282.26 | | EINECS: | | | Product Categories: | | | Mol File: | 2095417-52-8.mol |  |
| | 3'-Azido-3'-deoxy-5-methyl-beta-L-cytidine Chemical Properties |
| | 3'-Azido-3'-deoxy-5-methyl-beta-L-cytidine Usage And Synthesis |
| Uses | 3’-Azido-3’-deoxy-5-methyl-beta-L-cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. 3’-Azido-3’-deoxy-5-methyl-beta-L-cytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups. | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
| | 3'-Azido-3'-deoxy-5-methyl-beta-L-cytidine Preparation Products And Raw materials |
|